Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review

被引：20

作者：

Buzon-Martin, Luis ^{[1
,2
]}

Zollner-Schwetz, Ines ^{[3
]}

Tobudic, Selma ^{[4
]}

Cercenado, Emilia ^{[5
,6
,7
]}

Lora-Tamayo, Jaime ^{[2
,8
,9
]}

机构：

[1] Hosp Univ Burgos, Dept Internal Med, Infect Dis Div, Burgos 09006, Spain

[2] Spanish Soc Infect Dis & Clin Microbiol GEIO SEIM, Bone & Joint Infect Study Grp, Madrid 28003, Spain

[3] Med Univ Graz, Dept Internal Med, Sect Infect Dis & Trop Med, A-8036 Graz, Austria

[4] Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, A-1090 Vienna, Austria

[5] Hosp Gen Univ Gregorio Maranon, Serv Microbiol & Enfermedades Infecciosas, Madrid 28007, Spain

[6] CIBER Enfermedades Resp CIBERES, CB06-06-0058, Madrid 28029, Spain

[7] Univ Complutense Madrid, Sch Med, Med Dept, Madrid 28040, Spain

[8] Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre I 12, Dept Internal Med, Madrid 28041, Spain

[9] Red Espanola Invest Patol Infecciosa REIPI, Madrid 28029, Spain

来源：

ANTIBIOTICS-BASEL | 2021年 / 10卷 / 06期

关键词：

dalbavancin; prosthetic joint infection; gram-positive; IN-VITRO ACTIVITY; RESISTANT STAPHYLOCOCCUS-AUREUS; ONCE-WEEKLY DALBAVANCIN; UNITED-STATES; PHARMACOKINETICS; SKIN; SURVEILLANCE; BIOFILMS; SPECTRUM; THERAPY;

D O I：

10.3390/antibiotics10060656

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.

引用

页数：12

共 58 条

[1] Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care [J].

Ajaka, Leama ;

Heil, Emily ;

Schmalzle, Sarah .

ANTIBIOTICS-BASEL, 2020, 9 (10) :1-10

[2] In vivo pharmacodynamic activity of the glycopeptide dalbavancin [J].

Andes, David ;

Craig, William A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (05) :1633-1642

[3] Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) [J].

Ariza, Javier ;

Cobo, Javier ;

Baraia-Etxaburu, Josu ;

Benito, Natividad ;

Bori, Guillermo ;

Cabo, Javier ;

Corona, Pablo ;

Esteban, Jaime ;

Horcajada, Juan Pablo ;

Lora-Tamayo, Jaime ;

Murillo, Oscar ;

Palomino, Julian ;

Parra, Jorge ;

Pigrau, Carlos ;

del Pozo, Jose Luis ;

Riera, Melchor ;

Rodriguez, Dolores ;

Sanchez-Somolinos, Mar ;

Soriano, Alex ;

del Toro, M. Dolores ;

de la Torre, Basilio .

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2017, 35 (03) :189-195

[4] Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model [J].

Baldoni, Daniela ;

Tafin, Ulrika Furustrand ;

Aeppli, Sandrine ;

Angevaare, Eline ;

Oliva, Alessandra ;

Haschke, Manuel ;

Zimmerli, Werner ;

Trampuz, Andrej .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) :220-225

[5] Suppressive antibiotic treatment with dalbavancin. A case report [J].

Barbero Allende, Jose Maria ;

Garcia Sanchez, Marta ;

Culebras Lopez, Ana Maria ;

Agudo Alonso, Rosa .

REVISTA ESPANOLA DE QUIMIOTERAPIA, 2021, 34 (02) :151-153

[6] Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis [J].

Barnea, Yoav ;

Lerner, Anat ;

Aizic, Asaf ;

Navon-Venezia, Shiri ;

Rachi, Eleanor ;

Dunne, Michael W. ;

Puttagunta, Sailaja ;

Carmeli, Yehuda .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (02) :460-463

[7] Prosthetic Joint Infection Update [J].

Beam, Elena ;

Osmon, Douglas .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2018, 32 (04) :843-+

[8] Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates [J].

Biedenbach, Douglas J. ;

Bell, Jan M. ;

Sader, Helio S. ;

Turnidge, John D. ;

Jones, Ronald N. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :1260-1263

[9] In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) Staphylococcus aureus Isolates [J].

Bongiorno, Dafne ;

Lazzaro, Lorenzo Mattia ;

Stefani, Stefania ;

Campanile, Floriana .

ANTIBIOTICS-BASEL, 2020, 9 (12) :1-8

[10] Stewarding the Costly Antibiotic: Considerations for Dalbavancin [J].

Bookstaver, P. Brandon ;

Milgrom, Alex .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) :E1443-E1444

← 1 2 3 4 5 6 →